These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10638405)

  • 1. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study.
    Grünwald F; Kälicke T; Feine U; Lietzenmayer R; Scheidhauer K; Dietlein M; Schober O; Lerch H; Brandt-Mainz K; Burchert W; Hiltermann G; Cremerius U; Biersack HJ
    Eur J Nucl Med; 1999 Dec; 26(12):1547-52. PubMed ID: 10638405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer.
    Grünwald F; Menzel C; Bender H; Palmedo H; Willkomm P; Ruhlmann J; Franckson T; Biersack HJ
    Thyroid; 1997 Jun; 7(3):327-35. PubMed ID: 9226199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
    Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer.
    Grünwald F; Schomburg A; Bender H; Klemm E; Menzel C; Bultmann T; Palmedo H; Ruhlmann J; Kozak B; Biersack HJ
    Eur J Nucl Med; 1996 Mar; 23(3):312-9. PubMed ID: 8599963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
    Muros MA; Llamas-Elvira JM; Ramírez-Navarro A; Gómez MJ; Rodríguez-Fernández A; Muros T; López de la Torre M; Becerra A; Carreras JL
    Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value and therapeutic impact of (18)F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study.
    Riemann B; Uhrhan K; Dietlein M; Schmidt D; Kuwert T; Dorn R; Sciuk J; Kodalle T; Schober O
    Nuklearmedizin; 2013; 52(1):1-6. PubMed ID: 23192295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
    Ruiz Franco-Baux JV; Borrego Dorado I; Gómez Camarero P; Rodríguez Rodríguez JR; Vázquez Albertino RJ; Navarro González E; Astorga Jiménez R
    Rev Esp Med Nucl; 2005; 24(1):5-13. PubMed ID: 15701340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
    Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
    Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer.
    Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
    Eur J Nucl Med; 1997 Nov; 24(11):1342-8. PubMed ID: 9371865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG-PET in the follow-up of thyroid cancer.
    Lind P; Kresnik E; Kumnig G; Gallowitsch HJ; Igerc I; Matschnig S; Gomez I
    Acta Med Austriaca; 2003; 30(1):17-21. PubMed ID: 12558561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose.
    Caleo O; Maurea S; Klain M; Salvatore B; Storto G; Mancini M; Pace L; Salvatore M
    Radiol Med; 2008 Mar; 113(2):278-88. PubMed ID: 18386128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan.
    Wu HS; Huang WS; Liu YC; Yen RF; Shen YY; Kao CH
    Anticancer Res; 2003; 23(5b):4235-8. PubMed ID: 14666632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results.
    Stokkel MP; de Klerk JH; Zelissen PM; Koppeschaar HP; van Rijk PP
    Eur J Nucl Med; 1999 Dec; 26(12):1606-9. PubMed ID: 10638413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?
    Piccardo A; Foppiani L; Morbelli S; Bianchi P; Barbera F; Biscaldi E; Altrinetti V; Villavecchia G; Cabria M
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
    Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
    Hung MC; Wu HS; Kao CH; Chen WK; Changlai SP
    Endocr Res; 2003 May; 29(2):169-75. PubMed ID: 12856803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RADIOISOTOPE DIAGNOSTIC ALGORITHM FOR THE RELAPSE AND METASTASES DETECTION IN THE IODINE-NEGATIVE DIFFERENTIATED THYROID CANCER.
    Solodyannikova OI; Kmetyuk YV; Danilenko VV; Sukach GG
    Probl Radiac Med Radiobiol; 2020 Dec; 25():579-591. PubMed ID: 33361863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.